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Haematological malignancy is the major indication for allogenic
and autogenic bone marrow transplantation. Patients with certain
solid tumours (e.g. small-cell lung cancer, breast or ovarian
adenocarcinoma, germ cell tumours) may also undergo autografts,
but this is usually in the setting of a clinical trial. The prognosis
after bone marrow transplantation has been substantially im-
proved by progress made in the management of infectious
complications and immunosuppression (Rowe et al, 1994).
Unfortunately, many of the drugs used (antibiotics, cyclosporine,
etc.) have adverse effects, particularly metabolic and gastrointest-
inal effects. This is in addition to the side-effects of the
conditioning regimen (total body irradiation, myelosuppressive
chemotherapy), any graft complications (graft-versus-host (GVH)
disease and veno-occlusive disease) and disease response (tumour
lysis syndrome). Gastrointestinal and infectious complications are
frequent and often lead to a significant reduction in oral food
intake. In this situation, a protein-calorie deficiency can occur
rapidly and this may continue even after recovery of the bone
marrow.
OBJECTIVES
The objective of these guidelines is to define the role of enteral and
parenteral nutrition in the nutritional management of patients who
have undergone or who will undergo bone marrow transplanta-
tion. The role of some specific substrates and emulsions (e.g.
lipids, glutamine) in this clinical situation will also be considered.
There are several areas of controversy, for example, the role of
glutamine supplementation (Ribaud et al, 1997). The importance
and best means of nutritional management in patients who have
undergone or are about to undergo bone marrow transplantation
were addressed.
The questions addressed by the working group were:
 What are the clinical and metabolic consequences of malnutri-
tion?
 What factors should be taken into consideration in the
nutritional assessment of these patients?
 What is the efficacy of artificial nutrition (enteral or parenteral)
in terms of survival?
 What is the impact on risks and infectious complications?
 What nutritional support should be used (enteral or parenteral
nutrition)?
 What protein and lipid supplements should be used?
 What therapeutic strategies should be adopted?
METHODS
Full details of the methodology used have been published (Fervers
et al, 2001). A multidisciplinary working group was set up by the
French National Federation of Comprehensive Cancer Centres
(Fe ´de ´ration Nationale des Centres de Lutte Contre le Cancer –
FNCLCC) to review the best available evidence concerning
artificial nutrition in patients undergoing bone marrow transplan-
tation. A literature search of Medline
s from 1991 to 2001 and The
Cochrane Library
s (2001, issue 1) was performed. The search was
limited to articles published in English and French. Editorials,
letters, case reports and animal studies were eliminated by the
search strategy. The key words were bone marrow transplantation
or haematopoietic stem cell transplantation combined with
nutrition or nutrition assessment. A specific search for rando-
mised clinical trials was performed. Economic studies on this
subject were not taken into consideration. The resulting reference
list was completed with references from the personal reference
databases of the members of the working group, including one
reference published in Spanish.
Infection is the principle risk during bone marrow transplanta-
tion. Thus, the primary outcomes for evaluating the efficacy
of nutritional support in patients undergoing bone marrow
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infections and survival.
The secondary outcomes are:
 reduction in the length of hospitalisation in a bone marrow
transplantation unit;
 reduction of the incidence and severity of the GVH reactions;
 antibiotic use;
 reduction in the volume of red blood cell and platelet
transfusions;
 improved anthropometrical and laboratory parameters;
 time to the resolution of bone marrow suppression.
After selection and critical appraisal of the articles, the working
group developed the ‘Standards’, ‘Options’ and ‘Recommenda-
tions’ (SORs) for nutrition support in bone marrow transplant
patients based on the best available scientific evidence or on expert
agreement. These guidelines were then reviewed by a group of
independent experts (see the Appendix) and finalised after taking
into consideration their comments.
‘Standards’ identify clinical situations for which there exist
strong indications or contraindications for a particular interven-
tion, and ‘Options’ identify situations for which there are several
alternatives, none of which have shown clear superiority over the
others (Table 1). In any SOR, there can be several ‘Options’ for a
given clinical situation. ‘Recommendations’ enable the ‘Options’t o
be weighted according to the available evidence. Several interven-
tions can be recommended for the same clinical situation, so that
clinicians can make a choice according to specific clinical
parameters, for example, local circumstances, skills, equipment,
resources and patient preferences. The adaptation of the SOR to
the local situation is allowable if the reason for the choice is
sufficiently transparent and this is crucial for successful imple-
mentation. Inclusion of patients in clinical trials is an appropriate
form of patient management in oncology and is recommended
frequently within the SORs, particularly in situations where
evidence is too weak to support an intervention.
The type of evidence underlying any ‘Standard’, ‘Option’o r
‘Recommendation’, is indicated using a classification developed by
the Fe ´de ´ration Nationale des Centres de Lutte Contre le Cancer
(FNCLCC) based on previously published models. The level of
evidence depends not only on the type and quality of the studies
reviewed, but also on the concordance of the results (Table 2).
When no clear scientific evidence exists, judgement is made
according to the professional experience and consensus of the
working group (‘expert agreement’).
These guidelines will be updated when new scientific evidence
becomes available or when there is a change in expert agreement.
The French full text version has been published (Raynard et al,
2002) and is also available at: (http://www.fnclcc.fr). A French
summary version was produced, based on the full text, and this has
been translated into English here.
Clinical and metabolic consequences of malnutrition
Moderate malnutrition is frequent before bone marrow transplan-
tation (level of evidence: C). The prevalence of severe malnutrition
before bone marrow transplantation has not been accurately
assessed. Malnutrition is an independent risk factor for mortality
after bone marrow transplantation (level of evidence: C).
Severe malnutrition occurs rapidly in the absence of appropriate
nutritional support after myeloablative conditioning (level of
evidence: C). Gut disorders are the chief cause of malnutrition and
deficiency syndromes (level of evidence: C). Nitrogen deficiency is
often severe after myeloablative conditioning (level of evidence:
B2). A precise evaluation of the incidence of malnutrition in
patients who have undergone bone marrow transplantation is
necessary (recommendation, expert agreement).
Nutritional assessment and follow-up (Figure 1)
There is no standard. Nutritional assessment and follow-up can be
considered in patients who have undergone or are about to
undergo bone marrow transplantation (option). Routine nutri-
tional evaluation should be carried out before transplantation
(recommendation, expert agreement).
Modalities for nutritional assessment and follow-up and
for assessing protein-energy intake
The initial nutritional assessment should include a body weight
measurement and percentage loss of body weight (standard, expert
agreement). The initial nutritional evaluation can include assays
for albumin, transthyretin and C-reactive protein (option).
Nutritional follow-up (Figure 2) should include weekly determi-
nation of body weight, clinical surveillance of the hydration status
and weekly evaluation of oral food intake (standard, expert
agreement). Nutritional surveillance can include an assay for
transthyretin in the absence of liver and/or kidney failure (option).
The recommended daily nonprotein calorie intake is between 25
and 35kcalkg
1 and the recommended daily nitrogen intake is
between 200 and 250mgkg
1 (recommendation, expert agree-
ment).
Artificial nutrition
Artificial nutrition is indicated in patients after bone marrow
transplantation with myeloablative conditioning (standard) (Fig-
ures 3 and 4). In other situations, there is no routine indication for
artificial nutrition. The different modalities of nutritional support
available are artificial nutrition, intravenous hydration and oral
nutrition.
The recommendations depend on the patients’ initial nutritional
status and the expected duration of any gastrointestinal problems.
Table 1 Definition of ‘Standards, Options and Recommendations’
Standards Procedures or treatments that are considered to be of
benefit, inappropriate or harmful by unanimous decision,
based on the best available evidence
Options Procedures or treatments that are considered to be of
benefit, inappropriate or harmful by a majority, based
on the best available evidence
Recommendations Additional information to enable the available options
to be ranked using explicit criteria (e.g. survival toxicity)
with an indication of the level of evidence
Table 2 Definition of level of evidence
Level A
There exists a high-standard meta-analysis or several high-standard randomised
clinical trials, which give consistent results
Level B
There exist good quality evidence from randomised trials (B1) or prospective or
retrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent
when considered together
Level D
Either the scientific data do not exist or there is only a series of cases
Expert agreement
The data do not exist for the method concerned, but the experts are unanimous
in their judgement
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nonmyeloablative conditioning and whose oral intake is more
than 60% of the requirements, oral nutrition should be maintained
with intravenous hydration during hospitalisation (recommenda-
tion, expert agreement).
In patients who are not suffering from malnutrition after
myeloablative conditioning, artificial nutrition should be started
from day 1 (recommendation, expert agreement).
Artificial nutrition should be given to patients suffering from
malnutrition (more than 10% loss of body weight) irrespective of
the type of transplant or conditioning (recommendation, expert
agreement).
Oral or parenteral nutrition
There are no standard modalities for artificial nutrition (level of
evidence: B1). Total enteral or parenteral nutrition or enteral
nutrition combined with parenteral nutrition can be considered
(option). Enteral and parenteral nutrition give the same clinical
and metabolic results (level of evidence: B1).
Enteral nutrition is theoretically possible, but its safety is
variable (recommendation, level of evidence: B1). Enteral nutrition
rather than parenteral nutrition should be the preferred first-line
treatment in patients undergoing bone marrow transplantation
without myeloablative conditioning (recommendation, expert
agreement). This should be combined with parenteral nutrition
when the calorie-nitrogen intake is less than 60% of the
requirements (recommendation, expert agreement).
Total parenteral nutrition should be reserved for patients who
have an intolerance of oral or enteral nutrition, those who have an
obstruction in the digestive tract or those who have severe
mucositis (recommendation, expert agreement). Dietetic follow-up
should be continued for some time after the graft to facilitate
resumption of oral feeding and withdrawal from artificial nutrition
(recommendation, expert agreement). Randomised clinical trials
should be undertaken to compare enteral and parenteral nutrition
(recommendation, expert agreement).
Lipid intake
A lipid intake of 30% of the nonprotein energy intake, should be
used during bone marrow transplantation (standard, level of
evidence: B1) with no preference for medium-chain or long-chain
triglycerides (standard, level of evidence: B1). A lipid intake of
more than 30% can be considered without increasing the risk of
adverse effects (option, level of evidence: B1).
Other types of lipid emulsions should only be used in the setting
of a randomised clinical trial using relevant clinical outcomes in
patients undergoing bone marrow transplantation (recommenda-
tion, expert agreement). A reduction in the incidence of serious
GVH reactions by a high lipid intake should be confirmed
(recommendation, expert agreement).
Protein substrates
There is no justification for supplementation with nitrogen-
containing substrates or oral glutamine in the nutritional support
of these patients. Parenteral glutamine supplementation can be
considered (option). Nitrogen-containing substrates (glutamine,
branched chain amino acids, arginine, ornithine alpha-ketogluta-
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Figure 1 Assessment of the pretransplantation nutritional status.
Standards:
there is no standard
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assessment of the post transplantation 
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• daily body weight determination 
• clinical surveillance of hydration status
• daily assessment of oral intake
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transthyretine assay in the absence of liver
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 a bone marrow transplant
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Figure 2 Nutritional surveillance.
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(recommendation, expert agreement).
Strategies for nutritional support
Patients with myeloablative conditioning Artificial nutrition
should be considered in patients with myeloablative conditioning
(standard) (Figures 3 and 4). There are no standard modalities.
Enteral nutrition with or without intravenous glutamine, enteral
and parenteral nutrition, total parenteral nutrition with or without
intravenous glutamine can all be considered. Total parenteral
nutrition is recommended for patients with severe mucositis
(expert agreement). Artificial nutrition should be started on day 1
(expert agreement).
Patients without myeloablative conditioning There are no
standards. Artificial nutrition (enteral nutrition with or
without intravenous glutamine, enteral and parenteral
nutrition) intravenous hydration or oral nutrition can be
considered (Figures 3 and 4). Total parenteral nutrition is
recommended for patients with severe mucositis (expert agree-
ment).
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Figure 3 Management of patients with denutrition detected during pretransplantation assessment.
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Figure 4 Management of patients with no denutrition detected during pretransplantation assessment
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